Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial
Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial
The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.
Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week for 6 weeks.
This is a randomized, assessor-blinded study that involves the use of telerehabilitation to deliver additional therapy for persons with stroke. Patients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: [1] TR and usual care; [2] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes/day of activities targeting arm function, 6 days a week 6-8 weeks. The hypothesis of this study is patients receiving TR in addition to their usual care will have significantly greater recovery of arm function compared to patients receiving usual care alone.
Study participation will last approximately 8 months and includes 4 in-person visits. At these visits, patients will undergo a variety of assessments including tests of arm function and a single MRI scan of the brain. Patients undergoing TR will receive arm motor training, which consists of 36 sessions of assigned exercises, games, and stroke education; these total 70 minutes in length and occur 6 days a week for 6 weeks; TR subjects will also continue usual care. Patients in the usual care group only will not engage in TR but will instead continue all of the therapies recommended by their medical team. At the end of the study, participants in the usual care group will be offered TR.
Inclusion Criteria:
Exclusion Criteria:
tr2trial@mednet.ucla.edu(424)522-7874
Downey, California 90242, United States
jasong@ranchoresearch.org(562)385-6939
Washington D.C., District of Columbia 20010, United States
Miami, Florida 33136, United States
Chapel Hill, North Carolina 27514, United States
Elkins Park, Pennsylvania 19027, United States
Houston, Texas 77030, United States
ldodak@hs.uci.edu(949)824-8748
stuticha@usc.edu(626)642-8213
tr2trial@mednet.ucla.edu(424)522-7874
jgumarang@casacolina.org(909)596-7733
tmcquaid@health.ucsd.edu(619)543-4666
gabrielle.edwards@medstar.net(202)221-9998
taisiya.matev@brooksrehab.org(904)345-8973
drodriguez5@med.miami.edu(305)243-2797
smurph7@emory.edu(404)712-1928
smoores@kumc.edu(913)588-2697
jdicarlo2@mgh.harvard.edu(617)726-1311
wang.qingmei@mgh.harvard.edu(617)952-5299
abraham.madjidov@baystatehealth.org(208)571-0434
ddshin@umich.edu(734)615-3904
karolina.roszkowski@mountsinai.org929-637-5818
ms6431@cumc.columbia.edu(212)305-9416
jcassidy@med.unc.edu(919)843-5774
megan.gonzalez@duke.edu(919)668-7597
drurycd@ucmail.uc.edu(513)558-7656
khansen1@metrohealth.org(216)957-3584
poppenh@ccf.org(216)704-3675
tr2trial@mednet.ucla.edu(215)663-6400
roddeyt@musc.edu(843)725-8045
alyssa.miller@uth.tmc.edu(713)797-7132
Ruth.S.YanesBengoa@uth.tmc.edu(713)500-7934
amit.sethi@utah.edu(801)585-9292